Related Experiment Video
Updated: Jul 15, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
[Effect of tyrosine-kinase Inhibitor on p15 gene transfected K562 cells]
Wei Wang1, Bing-Zhong Sun, Hong Xie
1Department of Hematology, 175th Hospital of PLA, Zhangzhou 363000, China.
Abstract:
The objective of study was to investigate the combined effect of tyrosine-kinase inhibitor (imatinib) and p15 gene on the proliferation, cell cycle and apoptosis of chronic myeloid leukemia cell line K562. p15 gene was amplified from peripheral blood mononuclear cells by RT-PCR, and confirmed by DNA sequencing, then the recombinant p15-pcDNA3.1 vector was constructed and transfected into K562 cell line by Lipofectine. After screening with G418, p15-pcDNA3.1-K562 cell clone stably expressing P15 was isolated. P15 protein was identified by Western blot. The cell survival rate was determined by MTT, cell cycle and apoptosis were detected by flow cytometry. The results showed that partial deletion of p15 gene in K562 cells was verified by DNA sequencing, leading to the function of P15 protein to be lost. The expression of P15 protein can be detected by Western blot in p15-pcDNa3.1-K562 cells. A strong inhibition of cell proliferation was observed in p15-pcDNA3.1-K562 cells as compared with that of the control K562 cell. The cells of G(0)/G(1) phase in p15-pcDNA3.1-K562 cells increased apparently, and S phase cells declined signifcantly. Cell cycle was arrested in G(0)/G(1) phase. The percentage of apoptotic cells greatly increased after transfection with p15-pcDNA3.1-K562 cells combined with imatinib, and cell survival rate notably declined. It is concluded that the imatinib in combination with the expression of p15 gene has a synergistic effect on the inhibition of K562 cell proliferation and promotion of its apoptosis.
Insights
The study found that combining imatinib with p15 gene expression synergistically inhibits chronic myeloid leukemia (CML) cell proliferation and promotes apoptosis in K562 cells. Restoring p15 gene function significantly impacts CML cell behavior.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Context:
- Chronic myeloid leukemia (CML) is characterized by specific genetic mutations.
- The p15 gene plays a role in cell cycle regulation and tumor suppression.
- K562 cell line is a common model for CML research.
Purpose:
- To investigate the combined therapeutic effect of imatinib and p15 gene expression on K562 cells.
- To analyze the impact on cell proliferation, cell cycle, and apoptosis.
- To determine if restoring p15 gene function enhances imatinib's efficacy.
Summary:
- p15 gene deletion was confirmed in K562 cells, leading to loss of P15 protein function.
- Stable expression of p15 gene in K562 cells inhibited proliferation and induced G0/G1 cell cycle arrest.
- Combined treatment with imatinib and p15 gene expression significantly increased apoptosis and decreased survival rate.
Impact:
- The findings suggest a synergistic effect between imatinib and p15 gene expression in CML treatment.
- Restoring p15 gene function could be a potential strategy to enhance imatinib therapy for CML.
- This research provides insights into novel therapeutic approaches for CML.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Receptor Tyrosine Kinases
